Posts Tagged ‘rivaroxban’

RSS

November 3rd, 2012

Rivaroxaban Gains FDA Indications for Treating and Preventing DVT and PE

The FDA has expanded the indication for rivaroxaban (Xarelto, Johnson & Johnson) to include the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk for recurrent DVT and PE. The oral anticoagulant is already approved to reduce postsurgical risk for DVT and PE  after hip- and knee-replacement surgery and to reduce […]